WO1996000070A1 - Traitement du besoin de nicotine et/ou des symptomes de manque du fumeur au moyen d'une composition contenant de la nicotine et de la cafeine ou de la xanthine pour administration par voie orale - Google Patents
Traitement du besoin de nicotine et/ou des symptomes de manque du fumeur au moyen d'une composition contenant de la nicotine et de la cafeine ou de la xanthine pour administration par voie orale Download PDFInfo
- Publication number
- WO1996000070A1 WO1996000070A1 PCT/US1995/007381 US9507381W WO9600070A1 WO 1996000070 A1 WO1996000070 A1 WO 1996000070A1 US 9507381 W US9507381 W US 9507381W WO 9600070 A1 WO9600070 A1 WO 9600070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- caffeine
- nicotine
- composition
- composition according
- equivalent
- Prior art date
Links
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title claims abstract description 170
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title claims abstract description 85
- 229960001948 caffeine Drugs 0.000 title claims abstract description 85
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title claims abstract description 85
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 56
- 229960002715 nicotine Drugs 0.000 title claims abstract description 56
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 230000000391 smoking effect Effects 0.000 title claims abstract description 24
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 title claims abstract description 15
- 206010057852 Nicotine dependence Diseases 0.000 title claims abstract description 13
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title claims description 8
- 229940075420 xanthine Drugs 0.000 title claims description 3
- 239000002904 solvent Substances 0.000 claims description 14
- 239000007937 lozenge Substances 0.000 claims description 12
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 7
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 235000015218 chewing gum Nutrition 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229920001971 elastomer Polymers 0.000 claims description 6
- 229940112822 chewing gum Drugs 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 239000000806 elastomer Substances 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- 244000246386 Mentha pulegium Species 0.000 claims description 4
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 4
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 4
- 240000008042 Zea mays Species 0.000 claims description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 4
- 235000005822 corn Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 235000001050 hortel pimenta Nutrition 0.000 claims description 4
- 235000014749 Mentha crispa Nutrition 0.000 claims description 3
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 3
- 235000012550 Pimpinella anisum Nutrition 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims description 2
- 238000009505 enteric coating Methods 0.000 claims description 2
- 244000024873 Mentha crispa Species 0.000 claims 1
- 240000004760 Pimpinella anisum Species 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 229940098466 sublingual tablet Drugs 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- -1 glidants Substances 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000006186 oral dosage form Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 8
- 244000061176 Nicotiana tabacum Species 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 229920000591 gum Polymers 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 235000010356 sorbitol Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000036765 blood level Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000167854 Bourreria succulenta Species 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000019693 cherries Nutrition 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000011269 tar Substances 0.000 description 3
- 235000019505 tobacco product Nutrition 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 240000000896 Dyera costulata Species 0.000 description 2
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 244000078639 Mentha spicata Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000498779 Myristica Species 0.000 description 2
- 240000009023 Myrrhis odorata Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 241000779819 Syncarpia glomulifera Species 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 235000020303 café frappé Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940119201 cedar leaf oil Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- SSNZFFBDIMUILS-UHFFFAOYSA-N dodec-2-enal Chemical compound CCCCCCCCCC=CC=O SSNZFFBDIMUILS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000001739 pinus spp. Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011125 single therapy Methods 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229940036248 turpentine Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CBOBADCVMLMQRW-UHFFFAOYSA-N 2,6-dimethyloctanal Chemical compound CCC(C)CCCC(C)C=O CBOBADCVMLMQRW-UHFFFAOYSA-N 0.000 description 1
- MDVYIGJINBYKOM-UHFFFAOYSA-N 3-[[5-Methyl-2-(1-methylethyl)cyclohexyl]oxy]-1,2-propanediol Chemical compound CC(C)C1CCC(C)CC1OCC(O)CO MDVYIGJINBYKOM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920001412 Chicle Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 240000001794 Manilkara zapota Species 0.000 description 1
- 235000011339 Manilkara zapota Nutrition 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019944 Olestra Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- YNKMHABLMGIIFX-UHFFFAOYSA-N benzaldehyde;methane Chemical compound C.O=CC1=CC=CC=C1 YNKMHABLMGIIFX-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007936 buccal or sublingual tablet Substances 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015145 nougat Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical class OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Definitions
- Treatment of nicotine cravi ng and/or smoking withdrawal symptoms with an oral composition containi ng nicotine and caffeine or xanthine
- Chewing beeswax, eating candy and peppermints as well as cold turkey interruption have been tried without much success.
- the addition of chemicals designed to sicken the user or render smoking repulsive to the user have also not produced good results.
- More recent therapies for smoking cessation have focused on the administration of nicotine to the smoker. These therapies allow the individual to satisfy a nicotine habit while minimizing or eliminating side effects caused by absorbing nicotine through the lungs along with the other harmful by-products of combustion of tobacco.
- Nicotine supplementation has proven to be an effective therapy as an adjunct to smoking cessation in helping to reduce the craving for smoking and provide relief from smoking withdrawal symptoms. However, there are many smokers for whom nicotine supplementation alone is inadequate.
- a composition can be formulated which provides the combination of nicotine and caffeine or caffeine equivalent in a single therapy. It has also been discovered that such a combination may offer the advantage of providing treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms to a broader spectrum of smokers who wish to break the smoking habit. It has further been discovered that these compositions may also curb the appetite which may aid in reducing the weight gain that is commonly experienced by individuals who stop smoking.
- the present invention relates to an oral composition for the treatment of nicotine craving or smoking withdrawal symptoms comprising nicotine and caffeine or caffeine equivalent, wherein the composition delivers from about 0.05mg to about lOmg of nicotine, and from about 0. lmg to about 250mg of caffeine or caffeine equivalent.
- the present invention further relates to a method for providing treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms to a human or lower animal in need of such treatment comprising the administration of a safe and effective amount of an oral composition comprising nicotine, and caffeine or caffeine equivalent.
- the subject invention comprises nicotine, caffeine or caffeine equivalent, and preferably one or more pharmaceutically-acceptable carriers suitable for oral administration. These compositions are useful for the treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms.
- nicotine craving and “smoking withdrawal symptoms” as used herein both refer to any physical or psychological reaction relating to breaking the habit of smoking tobacco or using any tobacco product or decreasing the frequency or intensity of smoking tobacco or using any tobacco product.
- pharmaceutically-acceptable is used herein to describe materials that are non-toxic and suitable for administration to humans and/or lower animals.
- pharmaceutically-acceptable carrier as used herein means any material safe and effective for use in the compositions of the present invention.
- Such materials include pH adjusters, diluents, binders, lubricants, glidants, disintegrants, gum bases, elastomer solvents, liquid oral carriers, emollients, emulsifiers, buffering agents, solvents, preservatives, agents for regulating isotonicity, fillers, wetting agents, thickening agents, suspending agents, solubilizing agents, humectants, sweeteners, flavorings, plasticizers, bioadhesive compounds, surfactants, aromatic compounds, agents for aiding the film-forming properties and substantivity of the formulations, antimicrobials for maintaining the antimicrobial integrity of the compositions, antioxidants, agents suitable for aesthetic purposes such as fragrances, pigments, and colorings, non-soluble ingredients, and mixtures thereof.
- safe and effective amount mean a sufficient amount of material to provide the desired benefit without undue adverse side effects commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.
- the specific safe and effective amount will vary with such factors as the particular condition that is being treated, the severity of the condition, the duration of the treatment, the physical condition of the patient, the nature of concurrent therapy (if any), and the specific formulation and optional components hereinafter.
- suitable for oral administration refers to any formulation that is suitable for the convenient administration of the composition whereby the composition is taken into the mouth and swallowed, placed in contact with mucous membranes of the mouth, and/or throat and/or pharynx and dissolved slowly over a period of time, or taken into the mouth but not necessarily swallowed, e.g., chewing gum.
- the present invention comprises nicotine.
- Nicotine is a tertiary amine composed of a pyridine and a pyrrolidine ring. It is a colorless to pale yellow, which is freely water soluble, strongly alkaline, hygroscopic liquid obtained from the tobacco plant. Nicotine has a characteristic odor and turns brown on exposure to air or light [Physicians Desk Reference. 48th Edition, p. 1306, 1984]. Nicotine is delivered in an amount of from about 0.05mg to about lOmg, preferably from about 0.25mg to about 7.5mg, and most preferably from about 0.5mg to about 3mg. Nicotine is also described in Remington's Pharmaceutical Sciences. 18th Edition, 1990, p. 891, which is incorporated herein by reference. Caffeine
- the present inventions also comprise caffeine or a caffeine equivalent.
- Caffeine is found as white, fleecy masses or long, flexible, silky crystals. It is odorless, bitter tasting, and slightly soluble in water and alcohol. Caffeine may be derived synthetically or by extraction of coffee beans, tea leaves or kola nuts [Hawleys Condensed Chemical Dictionary. Twelfth Edition, 1993]. Examples of suitable sources of caffeine for use in the present invention are pure caffeine, caffeine combined with acetate, citrate, benzoate, phosphate, sulfate or salicylate. Also suitable are any of the xanthine analogues that match caffeine's effectiveness as a central nervous system stimulant, including salts thereof that are compatible.
- Xanthine derivatives are described in Remington's Pharmaceutical Sciences. 18th Edition, 1990, pp. 1132-34, which is incorporated herein by reference.
- the caffeine or caffeine equivalent is delivered in an amount of from about 0.1 mg to about 250mg, preferably from about lOmg to about 180mg, and most preferably from about 50mg to about 125mg.
- Pharmaceuticallv-Acceptable Carrier
- compositions preferably also contain one or more pharmaceutically-acceptable carriers suitable for oral administration.
- Such compositions include (but are not limited to) lozenges, chewing gums, sublingual delivery systems, capsules, gelcaps, caplets, syrups, aqueous solutions, suspensions, or other formulations suitable for administering the present compositions orally.
- the present compositions also include formulations which deliver the nicotine and/or caffeine or caffeine equivalent in a sustained release system or at varying intervals or levels throughout the oral administration of the composition.
- the carrier or carriers chosen must be suitable for administering the nicotine and caffeine or caffeine equivalent so that the desired blood levels of these compounds are achieved in the body of the recipient.
- the desired blood level of nicotine is from about lng/ml to about lOOng/ml, preferably from about 5ng/ml to about 75ng/ml, and most preferably from about lOng/ml to about 50ng/ml, preferably within 1-4 hours of administration.
- the desired blood level of caffeine or caffeine equivalent is from about O.Olug/ml to about 20ug ml, preferably from about 0. lug/ml to about 15ug/ml, and most preferably from about 0.5ug/ml to about lOug/ml, preferably within 1-4 hours of administration.
- compositions will normally be prepared in dosage unit form to contain safe and effective amounts of the nicotine and caffeine (or equivalent) to achieve the desired blood levels. Fractions of the dosage units or multiple dosage units may also be utilized.
- the oral compositions herein deliver to a human or lower animal from about 0.05mg to about lOmg, preferably from about 0.25mg to about 7.5mg, and most preferably from about 0.5mg to about 3mg of nicotine; and from about 0.1 mg to about 250mg, preferably from about lOmg to about 180mg, and most preferably from about 50mg to about 125mg, of caffeine or caffeine equivalent.
- the present invention may be an oral composition for the treatment of nicotine craving or smoking withdrawal symptoms comprising nicotine, caffeine or caffeine equivalent and one or more pharmaceutically-acceptable carriers suitable for oral administration, wherein the composition delivers from about 0.05mg to about lOmg of nicotine, and from about 0. lmg to about 250mg of caffeine or caffeine equivalent.
- the amount of nicotine and caffeine or caffeine equivalent and frequency of administration may vary depending on the carrier chosen and the personal needs of the user. However, it is suggested (as an example) that the present invention be administered from about once to about 12 times per day, preferably from about 3 to about 9 times per day, and most preferably from about 4 to about 8 times per day.
- compositions of the present invention may be in lozenge form.
- Lozenges are flavored solid dosage forms intended to be held in the mouth and sucked for slow dissolution and absorption by the oral mucosa. They may occur in various shapes and are generally formed either as compressed tablets or hard candies. Lozenges and their preparation are further described in Remington's Pharmaceutical Sciences, 18th Edition, 1990, pp. 1664-5, which is incorporated herein by reference. Lozenges prepared by compression are prepared similarly to any compressed tablet. This process provides a hard tablet which is desirable for slow dissolution in the mouth.
- These lozenges may include: fillers such as dicalcium phosphate, spray dried lactose, microcrystalline cellulose; disintegrating agents, lubricants, and glidants.
- Hard candy lozenges typically contain a base of sugar, flavored syrups such as high fructose corn syrups, and/or other carbohydrates.
- a base contains up to 92% corn syrup, up to 55% sugar, and from 0.1% to about 5% water. Additional ingredients may also be included such as flavorings, sweeteners, colorants, an adhesive substance such as mucilage or gum, acidulents, and the like.
- the base is heated and the lozenges are formed by molding and drying.
- Lozenges may also be formulated with soft confectionery materials such as those contained in nougat. These materials generally contain a high boiling syrup such as corn syrup or the like, and a relatively light textured frappe. Typically the frappe is prepared from gelatin, egg albumen, milk proteins such as casein, and vegetable proteins such as soy protein, and the like. Flavorings oils, additional sugar, and sweeteners may also be added.
- Solid oral dosage forms may be tablets, chewable tablets, caplets, capsules, gelcaps and other solid oral dosage forms known in the art. These forms include a buccal or sublingual tablet. Such a tablet is typically flat and oval and intended to be dissolved in the buccal pouch or beneath the tongue for absorption through the oral mucosa.
- the tablets may be compressed, titurated, freeze dried, sugar or film coated, or multiply compressed.
- the tablets may also contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, preservatives and flow-inducing agents.
- carrier materials suitable for preparation of unit dosage forms for oral administration are well-known in the art.
- compositions may also be in the form of a chewing gum.
- Such formulations typically comprise a gum base, elastomer solvents, plasticizers or softeners, fillers, flavorings, colorants, emulsifiers, and sweeteners.
- the gum base may be any water-insoluble gum base which includes (but is not limited to): natural elastomers including substances of vegetable origin such as chicle, jelutong, gutta percha, and crown gum; rubbers; and synthetic elastomers such as butadiene-styrene polymers, polyethylene, polyisobutylene, polyvinylacetate, and mixtures thereof.
- the gum base may be present at a level of from about 5% to about 45%, and preferably from about 15% to about 25%, by weight of the composition.
- suitable elastomer solvents may comprise methyl, glycerol or pentaerythritol esters of rosins or modified rosins, such as hydrogenated, dimerized or polymerized rosins or mixtures thereof.
- the elastomer solvents may be present at a level of from about 5% to about 75%, and preferably from about 35% to about 70%, by weight of the composition.
- Plasticizers or softeners may also be included to achieve a variety of textures and consistency properties.
- Such ingredients include without limitation: lanolin, stearic acid, sodium stearate, potassium stearate, glyceryl triacetate, glycerin, natural waxes, petroleum waxes, microcrystalline waxes, and mixtures thereof.
- Plasticizers or softeners may be present at a level of up to about 30%, and preferably from about 3% to about 20%, by weight of the composition.
- Fillers such as aluminum hydroxide, alumina, aluminum silicates, calcium carbonate, talc and mixtures thereof, may also be included at a level of from about 4% to about 30%, by weight of the composition.
- the present compositions may contain one or more solvents. Suitable solvents include but are not limited to water, alcohol, propylene glycol, glycerin, sorbitol solution and the like, to assist solubilization and incorporation of water-insoluble ingredients.
- the present invention may also be in a liquid oral dosage form. Liquid oral dosage forms include aqueous and nonaqueous solutions, emulsions, pseudo emulsions, suspensions, and solutions and/or suspensions reconstituted from non- effervescent granules. These dosage forms also contain suitable solvents, emulsifying agents, buffering agents, suspending agents, diluents, natural and artificial sweeteners, coloring agents, and flavoring agents.
- Antioxidants such as butylated hydroxy anisole or butylated hydroxy toluene, and preservatives such as methyl or propyl paraben or sodium benzoate may also be included.
- Specific examples of carriers and excipients that may be used to formulate oral dosage forms, are described by Roberts in U.S. Patent 3,903,297, issued September 2, 1975, which is incorporated herein by reference.
- Water-insoluble or poorly soluble ingredients may also be incorporated into aqueous-based orally acceptable carriers such as dispersions, suspensions, oil-in-water emulsions and the like by means of suitable dispersing, suspending or emulsifying agents, respectively, which are readily apparent to those skilled in the art of formulations.
- aqueous-based orally acceptable carriers such as dispersions, suspensions, oil-in-water emulsions and the like by means of suitable dispersing, suspending or emulsifying agents, respectively, which are readily apparent to those skilled in the art of formulations.
- aqueous-based orally acceptable carrier is one wherein the entire or predominant solvent content is water.
- Typical carriers include simple aqueous solutions, syrups, dispersions and suspensions, and aqueous based emulsions such as the oil-in-water type.
- the most preferred carrier is a suspension or solution of the phosphate derivative and active in an aqueous vehicle containing a suitable suspending or solubilizing agent.
- suitable suspending agents include celluloses, carboxymethyl cellulose and its salts, guar gum and the like.
- Suitable solubilizing agents include sucrose solutions, ethanol, and surfactants such as polyoxyethylene derivatives of fatty acid partial esters of sorbitol anhydrides (e.g., Polysorbate 80).
- Suspension systems, suspension and solubilizing agents, and methods for their use are described in M. Pernarowski, "Solutions, Emulsions and Suspensions” Remington's Pharmaceutical Sciences (A. Osol, editor, 15th Edition, 1975), which is incorporated herein by reference.
- typical oral formulations also contain a co-solvent including but not limited to alcohol, propylene glycol, glycerin, sorbitol solution, and the like, to assist solubilization and incorporation of water-insoluble ingredients, flavoring oils and the like into the composition.
- a co-solvent including but not limited to alcohol, propylene glycol, glycerin, sorbitol solution, and the like, to assist solubilization and incorporation of water-insoluble ingredients, flavoring oils and the like into the composition.
- the compositions may contain from about 5 to about 25 volume/volume percent of the co-solvent, most preferably from about 10 to about 20 volume/volume percent of the co-solvent.
- Non-aqueous carriers may also be used in the present compositions.
- Non ⁇ aqueous carriers include, without limitation, oil of animal, mineral or vegetable origin such as almond oil, olive oil, safflower oil, sunflower oil, and sucrose polyester (sold under the brand name Olestra).
- compositions may also comprise from about 0% to about 10%, preferably from about 2% to about 5%, of one or more pharmaceutically-acceptable emulsifiers.
- emulsifiers may be nonionic, anionic or cationic.
- Suitable emulsifiers are disclosed in, for example, U.S. Patent 3,755,560, issued August 28, 1973, Dicert et al.; U.S. Patent 4,421,769, issued December 20, 1983, Dixon et al.; and McCutcheon's Detergents and Emulsifiers. North American Edition, pages 317- 324 (1986); the disclosures of which are incorporated herein by reference.
- Preferred emulsifiers are anionic or nonionic, although the other types may also be used.
- Diluents, binders, lubricants, glidants, and disintegrants may also be included at al level of from about 0% to about 25%, and preferably from about 2% to about 20%, by weight of the composition.
- Suitable diluents include microcrystalline cellulose, mannitol, dicalcium phosphate, and celluloses.
- Binders useful include starch; gelatin; sugars such as sucrose, glucose and dextrose; natural and synthetic gums such as acacia, sodium alginate, ghatti gum, carboxymethylcellulose, and polyvinylpyrrolidine; polyethylene glycol, water, and alcohol.
- Lubricants include talc, magnesium stearate, stearic acid, polyethylene glycol, and hydrogenated vegetable oils.
- Glidants include colloidal silicon dioxide and disintegrants include starches, clays, celluloses, algins, gums, and cross-linked polymers.
- the present invention may also comprise one or more bioadhesive compounds which adhere to moist area of biological membranes. Such compounds include sodium carboxymethylcellulose, amyopectin, hydroxyethylcellulose, acrylates, gelatins, guar gum, karaya gum, tragacanth, agar, alginc acid, calcium carboxymethylcellulose, dextrin, methylcellulose, pectin, polyethylene glycol and polyvinylpyrrolidone.
- the bioadhesive compounds may be present at a level of from about 0.1% to about 30%, and preferably from about 7% to about 25%, by weight of the composition.
- a pharmaceutically-acceptable preservative is generally employed to increase the shelf life of the compositions.
- Benzyl alcohol is suitable, although a variety of preservatives including, for example, parabens, sodium benzoate, ascorbic acid, thimerosal, chlorobutanol, phenylmercuric acetate or benzalkonium chloride may also be employed.
- parabens, preservative system for use herein comprises a combination of benzalkonium chloride, chlorhexidine gluconate and disodium EDTA.
- a suitable concentration of the preservative will be from about 0.001% to about 2% based on the total weight, although there may be appreciable variation depending upon the agent selected.
- compositions of the present invention also include microencapsulation of either the nicotine or caffeine (or caffeine equivalent) or both.
- Techniques and materials for microencapsulation are well known in the art. Microencapsulation is discussed more fully in Kirk and Othmer's Encyclopedia of Chemical Technology. Vol. 13, 2nd Edition, pp.436-456, which is incorporated herein by reference.
- the nicotine and/or caffeine may also be protectively coated using techniques known in the art, such as an enteric coating, to protect the compounds in the gastrointestinal tract.
- compositions of the present invention may also contain one or more aromatic components.
- aromatics include, for example, menthol, eucalyptol, benzaldehyde (cherry, almond); citral (lemon, lime); neral; decanal (orange, lemon); aldehyde C-8, aldehyde C-9 and aldehyde C-12 (citrus fruits); tolyl aldehyde (cherry, almond); 2,6-dimethyl-octanal (green fruit); 2-dodecenal (citrus, mandarin); thymol; cedar leaf oil, myristica oil, lavender oil, nutmeg oil, turpentine; 3-1-menthoxy propane- 1,2-diol; N-substituted-p-menthane-3-carbox-amides and acyclic carboxamides; and mixtures thereof.
- Aromatic compounds may be present at a level of from about 0.0001% to about 1%, preferably from about 0.001% to about 1%, and most preferably from about 0.001% to about 0.5%, by weight of the compositions.
- the present compositions may also contain one or more flavorings.
- Suitable flavorings include both natural and artificial flavors, spearmint, peppermint, wintergreen, cinnamon, anise, vanilla, fruit essences including apple, peach, pear, strawberry, raspberry, cherry, pineapple, and the like, or any other flavorings that will effectively mask the taste of the nicotine and caffeine or caffeine equivalent.
- Preferred are peppermint, spearmint, anise, and fruit essences.
- Flavorings may be present at levels of from about 0% to about 5%, and preferably from about 0.5% to about 3%, by weight of the compositions.
- Sweetening agents suitable for use herein include any sweetener commercially available and suitable for human consumption such as sugars such as sucrose, glucose, dextrose, fructose, saccharin and its various salts, cyclamic acid and its salts, dipeptide sweeteners such as aspartame, and mixtures thereof.
- sugars such as sucrose, glucose, dextrose, fructose, saccharin and its various salts, cyclamic acid and its salts, dipeptide sweeteners such as aspartame, and mixtures thereof.
- dipeptide sweeteners such as aspartame, and mixtures thereof.
- a variety of additional optional pharmaceutically-acceptable ingredients may also be added to the present invention compositions.
- pH adjusters such as sodium hydroxide
- buffering agents such as sodium bicarbonate
- humectants such as urea, glycerol, sorbitols and glycerin
- thickeners such as methylcellulose, xanthan gum, and carbomer
- surfactants such as Tween 80 and Polyoxyl 40 Stearate
- various polymers for aiding the film-forming properties and substantivity of the formulations antimicrobials for maintaining the antimicrobial integrity of the compositions; antioxidants; and agents suitable for aesthetic purposes such as fragrances, pigments, and colorings.
- compositions may also contain low levels of pharmaceutically-acceptable insoluble ingredients added, for example, for visual effect purposes, e.g., thermochromic liquid crystalline materials such as the microencapsulated cholesteryl esters and chiral nematic (nonsterol) based chemicals such as the (2-methylbutyl) phenyl 4-alkyl(oxy)benzoates available form Hallcrest, Glenview, Illinois 60025, U.S.A.
- the method of providing treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms to a human or lower animal in need of such treatment as disclosed herein comprises the administration of a safe and effective amount of an oral composition comprising nicotine, and caffeine or caffeine equivalent.
- Such compositions preferably further comprise one or more pharmaceutically-acceptable carriers suitable for oral administration.
- the nicotine and caffeine or caffeine equivalent are administered in an oral carrier composition comprising both nicotine and caffeine (or caffeine equivalent)
- the desired blood levels of nicotine and caffeine be achieved through concurrent administration of nicotine and caffeine (or caffeine equivalent) but not necessarily by a carrier which comprises both compounds.
- caffeine be administered in a tablet formulation and that nicotine be administered concurrently by a transdermal delivery system.
- Another example is the administration of nicotine by an aqueous nasal spray and concurrent administration of caffeine by chewing gum.
- the present invention also encompasses a method for providing treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms to a human or lower animal in need of such treatment, comprising administering a safe and effective amount of nicotine and concurrently administering a safe and effective amount of caffeine or caffeine equivalent.
- a method for providing treatment and/or relief of nicotine craving and/or smoking withdrawal symptoms comprising administering a safe and effective amount of nicotine and concurrently administering a safe and effective amount of caffeine or caffeine equivalent.
- concurrently mean that the safe and effective amounts of nicotine and caffeine or caffeine equivalent are administered simultaneously or within 6 hours of each other.
- nicotine and/or caffeine or caffeine equivalent may be concurrently administered through a variety of embodiments or carriers as long as the desired blood levels taught in the present invention are achieved.
- embodiments or carriers include without limitation: intranasal delivery systems such as nasal drops, nasal sprays, nasal gels, ointments applied in the nasal cavity and systems which allow for the inhalation of vapors produced by nicotine or caffeine (or caffeine equivalent); transdermal and transmucosal delivery systems; and oral delivery systems or carriers such as those disclosed herein.
- EXAMPLE ⁇ The following is a chewing gum composition of the present invention. Ingredient Weight %
- liquid oral dosage form composition according to the present invention is prepared having the following components:
- Alcohol 10.00 Mix together sucrose and about 1/3 the amount of water and heat to about
- sucrose 60°C until sucrose is dissolved.
- Add flavor. Mix together sucrose solution with propylene glycol solution. Mix together this solution and potassium sorbate solution. Lastly, add flavor solution. Adjust water level for proper batch size. Adjust pH to about 6.5- 8.5. Mix for 30-35 minutes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne une composition administrée par voie orale, destinée au traitement du besoin de nicotine ou des symptômes de manque du fumeur, ladite composition contenant de la nicotine et de la caféine ou un équivalent de la caféine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU27708/95A AU2770895A (en) | 1994-06-23 | 1995-06-09 | Treatment of nicotine craving and/or smoking withdrawal symptoms with an oral composition containing nicotine and caffeine or xanthine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26455494A | 1994-06-23 | 1994-06-23 | |
US08/264,554 | 1994-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996000070A1 true WO1996000070A1 (fr) | 1996-01-04 |
Family
ID=23006582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/007381 WO1996000070A1 (fr) | 1994-06-23 | 1995-06-09 | Traitement du besoin de nicotine et/ou des symptomes de manque du fumeur au moyen d'une composition contenant de la nicotine et de la cafeine ou de la xanthine pour administration par voie orale |
Country Status (6)
Country | Link |
---|---|
AU (1) | AU2770895A (fr) |
IL (1) | IL114128A0 (fr) |
MA (1) | MA23587A1 (fr) |
PE (1) | PE41096A1 (fr) |
WO (1) | WO1996000070A1 (fr) |
ZA (1) | ZA955031B (fr) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034605A1 (fr) * | 1996-03-21 | 1997-09-25 | Mayo Foundation For Medical Education And Research | Utilisation de nicotine pour traiter une hepatopathie |
WO1997042941A3 (fr) * | 1996-05-13 | 1997-12-24 | Novartis Consumer Health Sa | Systeme de liberation gingivo-jugal |
WO1998003175A1 (fr) * | 1996-07-18 | 1998-01-29 | International Diabetes Institute | Traitement de l'obesite |
EP0828489A1 (fr) * | 1996-03-13 | 1998-03-18 | Yale University | Traitements pour cesser de fumer impliquant l'utilisation de naltrexone et de composes associes |
US6165516A (en) * | 1996-11-27 | 2000-12-26 | Wm. Wrigley Jr. Company | Method of controlling release of caffeine in chewing gum |
DE20018196U1 (de) | 2000-10-25 | 2001-01-11 | Peter, Michael N., 22297 Hamburg | Erzeugnis aus Zuckerware für Raucherentwöhnung |
US6949264B1 (en) | 1996-11-27 | 2005-09-27 | Wm. Wrigley Jr. Company | Nutraceuticals or nutritional supplements and method of making |
US7078052B2 (en) | 1999-04-06 | 2006-07-18 | Wm. Wrigley Jr. Company | Pharmaceutical chewing gum formulations |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7115288B2 (en) | 2000-06-09 | 2006-10-03 | Wm. Wrigley Jr. Company | Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener |
US7163705B2 (en) | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
EP1938806A1 (fr) | 2003-09-05 | 2008-07-02 | Arrow No. 7 Ltd. | Administration de médicaments par voie orale |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US7537009B2 (en) | 2001-06-05 | 2009-05-26 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US7581540B2 (en) | 2004-08-12 | 2009-09-01 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
WO2012083947A1 (fr) * | 2010-12-21 | 2012-06-28 | Fertin Pharma A/S | Composition de chewing-gum comprenant du poly(acide acrylique) réticulé |
US8991387B2 (en) | 2003-05-21 | 2015-03-31 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
EP3033951A1 (fr) * | 2005-05-25 | 2016-06-22 | U.S. Smokeless Tobacco Company LLC | Compositions de tabac |
US10098376B2 (en) | 2003-11-07 | 2018-10-16 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
WO2022049256A1 (fr) * | 2020-09-03 | 2022-03-10 | Nicoventures Trading Limited | Compositions et procédés |
CN115590855A (zh) * | 2022-10-26 | 2023-01-13 | 江南大学(Cn) | 一种降低尼古丁制品中尼古丁含量的方法 |
US11642473B2 (en) | 2007-03-09 | 2023-05-09 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US12214118B2 (en) | 2018-02-02 | 2025-02-04 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1901277A1 (de) * | 1969-01-10 | 1970-08-06 | Partipharm Ag | Mittel zur Kompensation uebermaessigen Zigarettenkonsums |
DE1617418A1 (de) * | 1967-12-16 | 1971-03-25 | Albert Ag Chem Werke | Herstellung von Arzneimitteln mit verzoegerter Wirkstoffabgabe |
US4568676A (en) * | 1983-11-25 | 1986-02-04 | Thomas Jefferson University | Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor |
DE3506406A1 (de) * | 1985-02-23 | 1986-08-28 | Hans-Josef 5600 Wuppertal Stromberg | Vorrichtung zur entwoehnung von ess-, trink-, rauch- und/oder suchtgewohnheiten |
US4778677A (en) * | 1981-07-09 | 1988-10-18 | Ebbesen Gerald K | Method for treatment of nicotine craving |
WO1991001132A1 (fr) * | 1989-07-24 | 1991-02-07 | Fertin Laboratories Ltd. (Dansk Tyggegummi Fabrik A/S) | Composition de chewing-gum a liberation reglee et acceleree des agents actifs |
US5051426A (en) * | 1990-03-27 | 1991-09-24 | Parnell Pharmaceuticals, Inc. | Method for effecting withdrawal from drug dependency |
EP0472428A2 (fr) * | 1990-08-23 | 1992-02-26 | Wm. Wrigley Jr. Company | Chewing gum à humidité réduite |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
-
1995
- 1995-05-16 MA MA23930A patent/MA23587A1/fr unknown
- 1995-06-09 WO PCT/US1995/007381 patent/WO1996000070A1/fr active Application Filing
- 1995-06-09 AU AU27708/95A patent/AU2770895A/en not_active Abandoned
- 1995-06-13 IL IL11412895A patent/IL114128A0/xx unknown
- 1995-06-19 ZA ZA955031A patent/ZA955031B/xx unknown
- 1995-06-22 PE PE1995272087A patent/PE41096A1/es not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1617418A1 (de) * | 1967-12-16 | 1971-03-25 | Albert Ag Chem Werke | Herstellung von Arzneimitteln mit verzoegerter Wirkstoffabgabe |
DE1901277A1 (de) * | 1969-01-10 | 1970-08-06 | Partipharm Ag | Mittel zur Kompensation uebermaessigen Zigarettenkonsums |
US4778677A (en) * | 1981-07-09 | 1988-10-18 | Ebbesen Gerald K | Method for treatment of nicotine craving |
US4568676A (en) * | 1983-11-25 | 1986-02-04 | Thomas Jefferson University | Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor |
DE3506406A1 (de) * | 1985-02-23 | 1986-08-28 | Hans-Josef 5600 Wuppertal Stromberg | Vorrichtung zur entwoehnung von ess-, trink-, rauch- und/oder suchtgewohnheiten |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
WO1991001132A1 (fr) * | 1989-07-24 | 1991-02-07 | Fertin Laboratories Ltd. (Dansk Tyggegummi Fabrik A/S) | Composition de chewing-gum a liberation reglee et acceleree des agents actifs |
US5051426A (en) * | 1990-03-27 | 1991-09-24 | Parnell Pharmaceuticals, Inc. | Method for effecting withdrawal from drug dependency |
EP0472428A2 (fr) * | 1990-08-23 | 1992-02-26 | Wm. Wrigley Jr. Company | Chewing gum à humidité réduite |
Non-Patent Citations (5)
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0828489A1 (fr) * | 1996-03-13 | 1998-03-18 | Yale University | Traitements pour cesser de fumer impliquant l'utilisation de naltrexone et de composes associes |
EP0828489A4 (fr) * | 1996-03-13 | 2001-04-04 | Univ Yale | Traitements pour cesser de fumer impliquant l'utilisation de naltrexone et de composes associes |
WO1997034605A1 (fr) * | 1996-03-21 | 1997-09-25 | Mayo Foundation For Medical Education And Research | Utilisation de nicotine pour traiter une hepatopathie |
CZ298212B6 (cs) * | 1996-05-13 | 2007-07-25 | Novartis Consumer Health S. A. | Pomalu se rozpadající pastilka |
WO1997042941A3 (fr) * | 1996-05-13 | 1997-12-24 | Novartis Consumer Health Sa | Systeme de liberation gingivo-jugal |
US6183775B1 (en) | 1996-05-13 | 2001-02-06 | Novartis Consumer Health S.A. | Buccal delivery system |
WO1998003175A1 (fr) * | 1996-07-18 | 1998-01-29 | International Diabetes Institute | Traitement de l'obesite |
US6165516A (en) * | 1996-11-27 | 2000-12-26 | Wm. Wrigley Jr. Company | Method of controlling release of caffeine in chewing gum |
US6949264B1 (en) | 1996-11-27 | 2005-09-27 | Wm. Wrigley Jr. Company | Nutraceuticals or nutritional supplements and method of making |
US7163705B2 (en) | 1998-12-15 | 2007-01-16 | Wm. Wrigley Jr. Company | Coated chewing gum product and method of making |
US7078052B2 (en) | 1999-04-06 | 2006-07-18 | Wm. Wrigley Jr. Company | Pharmaceutical chewing gum formulations |
US7115288B2 (en) | 2000-06-09 | 2006-10-03 | Wm. Wrigley Jr. Company | Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener |
DE20018196U1 (de) | 2000-10-25 | 2001-01-11 | Peter, Michael N., 22297 Hamburg | Erzeugnis aus Zuckerware für Raucherentwöhnung |
US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US9440034B2 (en) | 2001-05-24 | 2016-09-13 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US10350157B2 (en) | 2001-05-24 | 2019-07-16 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US11065400B2 (en) | 2001-06-05 | 2021-07-20 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US9687487B2 (en) | 2001-06-05 | 2017-06-27 | Alexza Pharmaceuticals, Inc. | Aerosol forming device for use in inhalation therapy |
US7537009B2 (en) | 2001-06-05 | 2009-05-26 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US9439907B2 (en) | 2001-06-05 | 2016-09-13 | Alexza Pharmaceutical, Inc. | Method of forming an aerosol for inhalation delivery |
US8955512B2 (en) | 2001-06-05 | 2015-02-17 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US9308208B2 (en) | 2001-06-05 | 2016-04-12 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US9370629B2 (en) | 2003-05-21 | 2016-06-21 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US8991387B2 (en) | 2003-05-21 | 2015-03-31 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US8603517B2 (en) | 2003-09-05 | 2013-12-10 | Gelmedic Holdings APS | Buccal drug delivery |
EP1938806A1 (fr) | 2003-09-05 | 2008-07-02 | Arrow No. 7 Ltd. | Administration de médicaments par voie orale |
US8343532B2 (en) | 2003-09-05 | 2013-01-01 | Arrow No. 7 Limited | Buccal drug delivery |
US8603516B2 (en) | 2003-09-05 | 2013-12-10 | Gelmedic Holding Aps | Buccal drug delivery |
US10945454B2 (en) | 2003-11-07 | 2021-03-16 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US10765140B2 (en) | 2003-11-07 | 2020-09-08 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US10098376B2 (en) | 2003-11-07 | 2018-10-16 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
US7581540B2 (en) | 2004-08-12 | 2009-09-01 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
EP3033951A1 (fr) * | 2005-05-25 | 2016-06-22 | U.S. Smokeless Tobacco Company LLC | Compositions de tabac |
US11642473B2 (en) | 2007-03-09 | 2023-05-09 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US12138383B2 (en) | 2007-03-09 | 2024-11-12 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US9707175B2 (en) | 2010-12-21 | 2017-07-18 | Fertin Pharma A/S | Chewing gum composition comprising cross-linked polyacrylic acid |
WO2012083947A1 (fr) * | 2010-12-21 | 2012-06-28 | Fertin Pharma A/S | Composition de chewing-gum comprenant du poly(acide acrylique) réticulé |
US12214118B2 (en) | 2018-02-02 | 2025-02-04 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
US12214119B2 (en) | 2018-02-02 | 2025-02-04 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
WO2022049256A1 (fr) * | 2020-09-03 | 2022-03-10 | Nicoventures Trading Limited | Compositions et procédés |
CN115590855A (zh) * | 2022-10-26 | 2023-01-13 | 江南大学(Cn) | 一种降低尼古丁制品中尼古丁含量的方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2770895A (en) | 1996-01-19 |
ZA955031B (en) | 1996-02-08 |
PE41096A1 (es) | 1996-10-08 |
MA23587A1 (fr) | 1995-12-31 |
IL114128A0 (en) | 1995-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996000070A1 (fr) | Traitement du besoin de nicotine et/ou des symptomes de manque du fumeur au moyen d'une composition contenant de la nicotine et de la cafeine ou de la xanthine pour administration par voie orale | |
US20210093563A1 (en) | Medicinal delivery system and related methods | |
AU2002359152B2 (en) | A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity | |
DK2023958T3 (en) | PHARMACEUTICAL PRODUCT FOR INTRAORAL DELIVERY OF NICOTINE COMPREHENSIVE TROMETAMOL AS BUFFER | |
JP4358787B2 (ja) | 改良されたニコチン舐剤 | |
CN102770138B (zh) | 含有尼古丁的软凝胶锭剂 | |
AU2008251095B2 (en) | Oral nicotine formulation buffered with amino acid | |
US20070163610A1 (en) | Formulation and Use and Manufacture Thereof | |
WO2017098443A1 (fr) | Composition thérapeutique enrichie en protéines d'un composé nicotinique | |
JP2004520389A (ja) | 性的不全の治療のための早期効果発現薬剤 | |
JP2012505878A (ja) | 複数部分口内剤形及びその使用 | |
JP2006503046A (ja) | 放出が改変された経口製剤 | |
Gadhavi et al. | Medicated Chewing Gum-A 21st Century Drug Delivery Sysytem | |
AU2013269448B2 (en) | Composition for preventing headaches | |
US20030198669A1 (en) | Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine | |
AU2012241150B2 (en) | Medicinal delivery system and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TT UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |